Myrexis is a biopharmaceutical company based in Salt Lake City, Utah, USA. It focused on drug development in several areas of medicine, in particular cancer therapy and auto-immune diseases. It was founded in 1999 as a spin-off from Myriad Genetics[1] and was originally known as Myriad Pharmaceuticals. Richard B. Brewer was its CEO from May 2012 until his death in August 2012.[2][3]
In February 2012 the company announced they had suspended development activity on all of its clinical and preclinical programs and appointed an investment company Stifel Nicolaus Weisel to evaluate strategic alternatives.[4] In November 2012, the board of Myrexis announced that it planned to put the company into liquidation subject to shareholder approval.[5] In January 2013, the board reversed its decision, cancelled the liquidation, declared a special cash distribution to shareholders and appointed Jonathan M. Couchman (chairman of Xselos Holdings) as president and chief executive officer. The remaining members of the board then resigned.[6]
